novo nordisk glp 1 launches Wegovy weight-loss pill in US, triggering price war | Pharmaceuticals industry Novo Nordisk CEO explains why

Semaglutide is less effective at reducing body weight in T2D patients compared to patients without (5% weight loss, SUSTAIN-6 and 15% weight loss, STEP, respectively)

9-13 In two of the trials, there was a significant association between the use of a synthetic GLP-1/GIP agonist and worse eye-related outcomes

Meanwhile, new GLP-1/GIP dual receptor agonists have been proven effective in neuroprotection and mechanisms in PD, such as DA-JC1 (DA1), DA-JC4 (DA4), and DA-CH5 (DA5) in MPTP-induced PD models

The body defends against weight loss through mechanisms that increase hunger, reduce energy expenditure, and enhance nutrient absorption efficiency

Articles were excluded based on the following criteria: (1) article not written in English

So, what exactly is microdosing GLP-1s, how does it work, and is it right for you